Journal of Crohn's and Colitis
Volume 6, Issue 1 , Pages 13-20 , February 2012

Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases: TAFIa level in patients with IBD

  • Danuta Owczarek

      Affiliations

    • Department of Gastroenterology, Hepatology and Infectious Diseases Jagiellonian University School of Medicine, Krakow, Poland
    • Corresponding Author InformationCorresponding author at: Department of Gastroenterology, Śniadeckich 5 31-531 Kraków, Poland.
    • ,
  • Anetta Undas

      Affiliations

    • Institute of Cardiology, Jagiellonian University School of Medicine, Krakow, Poland
    • ,
  • Jonathan H. Foley

      Affiliations

    • Department of Biochemistry, Queen's University, Kingston, Ontario, Canada
    • ,
  • Michael E. Nesheim

      Affiliations

    • Department of Biochemistry, Queen's University, Kingston, Ontario, Canada
    • Medicine, Queen's University, Kingston, Ontario, Canada
    • ,
  • Konrad Jabłonski

      Affiliations

    • Department of Gastroenterology, Hepatology and Infectious Diseases Jagiellonian University School of Medicine, Krakow, Poland
    • ,
  • Tomasz Mach

      Affiliations

    • Department of Gastroenterology, Hepatology and Infectious Diseases Jagiellonian University School of Medicine, Krakow, Poland

Received 7 February 2011 ,Revised 11 June 2011 ,Accepted 12 June 2011.

References 

  1. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417–430
  2. Tsiolakidou G, Koutroubakis IE. Trombosis and inflammatory bowel disease—the role of genetic risk factors. World J Gastroenterol. 2008;14:4440–4444
  3. Papa A, Scaldaferri F, Danese S, Guglielmo S, Roberto I, Bonizzi M, et al. Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. Dig Dis. 2008;26:149–155
  4. Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Strömqvist M, et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost. 2000;84:364–368
  5. Rooth E, Wallen H, Antovic A, von Arbin M, Kaponides G, Wahlgren N, et al. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul Fibrinolysis. 2007;18:365–370
  6. Donmez A, Aksu K, Celik HA, Keser G, Cagirgan S, Omay SB, et al. Thrombin activatable fibrinolysis inhibitor in Behcet's disease. Thromb Res. 2005;115:287–292
  7. Peters MJ, Nurmohamed MT, van Eijk IC, Verkleij CJ, Marx PF. Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1232–1233
  8. Yano Y, Kitagawa N, Gabazza EC, Morioka K, Urakawa H, Tanaka T, et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab. 2003;88:736–741
  9. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 1996;88:2093–2100
  10. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin–thrombomodulin complex. J Biol Chem. 1996;271:16603–16608
  11. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998;273:27176–27181
  12. Leung LL, Nishimura T, Myles T. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Adv Exp Med Biol. 2008;632:61–69
  13. Saibeni S, Bottasso B, Spina L, Bajetta M, Danese S, Gasbarrini A, et al. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol. 2004;99:1966–1970
  14. Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2008;20:912–916
  15. Stenson WF. Inflammatory bowel diseases. In:  Yamada T editors. 2nd ed. Textbook of gastroenterology. Vol. 2:Philadelphia: JB Lippincott; 1995;p. 1761–1772
  16. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753
  17. Rentsch M, Beham A, Schlitt HJ, Jauch KW. Crohn's disease activity index and Vienna classification—is it worthwhile to calculate before surgery?. Dig Surg. 2006;23:241–249
  18. van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut. 2004;53:1646–1651
  19. Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2010;16:52–57
  20. Malm L, Laurell M, Dahlback B. Changes in the plasma levels of vitamin-K dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol. 1988;68:437–443
  21. Kim PY, Foley J, Hsu G, Kim PY, Nesheim ME. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal Biochem. 2008;372:32–40
  22. Hataji O, Taguchi O, Gabazza EC, Yuda H, D'Alessandro-Gabazza CN, Fujimoto H, et al. Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol. 2004;76:214–219
  23. Brouns R, Heylen E, Willemse JL, Sheorajpanday R, De Surgeloose D, Verkerk R, et al. The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome. J Thromb Haemost. 2010;8:75–80
  24. Tregouet DA, Schnabel R, Alessi MC, Godefroy T, Declerck PJ, Nicaud V, et al. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost. 2009;7:49–57
  25. Te Velde EA, Wagenaar GT, Reijerkerk A, Roose-Girma M, Borel RI, Voest EE, et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost. 2003;1:2087–2096
  26. Kawamura T, Okada N, Okada H. Elastase from activated human neutrophils activates procarboxypeptidase R. Microbiol Immunol. 2002;46:225–230
  27. van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol. 2002;116:173–177
  28. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol. 2004;24:1374–1383
  29. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem. 2003;278:51059–51067
  30. Kume K, Yamasaki M, Tashiro M, Yoshikawa I, Otsuki M. Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis. Intern Med. 2007;46:1323–1329
  31. Kjeldsen J, Lassen JF, Brandslund I, Schaffalitzky de Muckadell OB. Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease. Scand J Gastroenterol. 1998;33:637–643
  32. Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al Lazikani B, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet. 2006;367:668–678
  33. Moss AC, Farrell RJ. Impotent immune system: an underlying problem in Crohn's disease. Gastroenterology. 2007;132:2609–2611
  34. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Il-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem. 2002;277:1021–1030
  35. Foley JH, Kim PY, Nesheim ME. TAFI zymogen does not play a significant role in the attenuation of fibrinolysis. J Biol Chem. 2008;283:8863–8867

PII: S1873-9946(11)00180-2

doi: 10.1016/j.crohns.2011.06.005

Journal of Crohn's and Colitis
Volume 6, Issue 1 , Pages 13-20 , February 2012

Article Tools

* Image Usage & Resolution